• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Eliquis (apixaban)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Eliquis (apixaban)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Eliquis (apixaban) is an orally available Factor Xa antagonist. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

    Eliquis is specifically indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

    Eliquis is supplied as a capsule for oral administration. The recommended dose for most patients is 5 mg taken orally twice daily. The recommended dose of Eliquis is 2.5 mg twice daily in patients with any two of the following characteristics: > age 80 years, body weight <60 kg, serum creatinine is >1.5 mg/dL. When Eliquis is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp, the recommended dose is 2.5 mg twice daily.

    Clinical Results

    FDA Approval
    The FDA approval of Eliquis was based on two clinical trials, ARISTOTLE and AVERROES.
    ARISTOTLE
    This multinational, double-blind study enrolled 18,201 subjects with nonvalvular atrial fibrillation (AF). The subjects were randomized to Eliquis 5 mg orally twice daily (or 2.5 mg twice daily in subjects meeting certain parameters- see above) or to warfarin . The trial was designed to compare the effects of Eliquis and warfarin on the risk of stroke and non-central nervous system (CNS) systemic embolism. The primary endpint was the non-inferiority of Eliquis to warfarin in reducing the risk of stroke (ischemic or hemorrhagic) and systemic embolism. Superiority of Eliquis to warfarin was also examined for the primary endpoint (rate of stroke and systemic embolism), major bleeding, and death from any cause. The subjects were followed for a median of 89 weeks. Eliquis was superior to warfarin for the primary endpoint of reducing the risk of stroke and systemic embolism (Eliquis: 212 subjects (1.27%) versus warfarin (265 subjects (1.60%); p=0.01). Eliquis also showed significantly fewer major bleeds than warfarin. Eliquis also resulted in a significantly lower rate of all-cause death (p = 0.046) than did treatment with warfarin, primarily because of a reduction in cardiovascular death, particularly stroke deaths. Non-vascular death rates were similar in the treatment arms.
    AVERROES
    This trial enrolled 5,598 subjects with nonvalvular atrial fibrillation thought not to be candidates for warfarin therapy. Subjects were randomized to treatment with Eliquis 5 mg orally twice daily (or 2.5 mg twice daily in selected patients) or aspirin 81 to 324 mg once daily. The primary objective of the study was to determine if Eliquis was superior to aspirin for preventing the composite outcome of stroke or systemic embolism. AVERROES was stopped early on the basis of a prespecified interim analysis showing a significant reduction in stroke and systemic embolism for Eliquis compared to aspirin that was associated with a modest increase in major bleeding.

    Side Effects

    The most common adverse events associated with the use of Eliquis are related to bleeding.

    Mechanism of Action

    Eliquis (apixaban) is an orally available Factor Xa antagonist. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

    Literature References

    Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf S, Lip GY, Hart RG Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial. Stroke 2012 Dec;43(12):3291-7

    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2011 Sep 15;365(11):981-92

    Additional Information

    For additional information regarding Eliquis or stroke and systemic embolism resulting from nonvalvular atrial fibrillation, please visit the Eliquis web page.

    Approval Date: 2012-12-01
    Company Name: Bristol-Myers Squibb
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing